肿瘤过继性细胞免疫治疗中CAR-T及TCR-T疗法研究进展

近年来,新的生物技术不断被应用于临床,其中的肿瘤免疫治疗就是一种新型的抗肿瘤疗法。免疫治疗指在肿瘤微环境中,通过刺激免疫功能,增强抗肿瘤免疫,进而直接识别和杀伤肿瘤细胞。目前被应用于临床的肿瘤免疫治疗方法有免疫检查点治疗、细胞因子、肿瘤疫苗、过继性细胞免疫治疗（ACI）等。ACI是重要的肿瘤免疫治疗方法,由于ACI可以在不损害免疫系统及其功能的情况下杀死肿瘤细胞,而且能够避免肿瘤免疫逃逸,所以成为国内外研究的热点。经基因修饰改造T 淋巴细胞是ACI临床应用研究最深入的领域。经基因修饰改造的T淋巴细胞可分为嵌合抗原受体T细胞（CAR-T）及T细胞受体改造的T细胞（TCR-T）,该文就CAR-T及TCR-T疗法的研究进展进行综述。

Research progress on CAR-T and TCR-T in adoptive cellular immunotherapy for tumors

In recent years, novel biological technologies have been constantly applied in clinical practice. Immunotherapy is considered as a new type of anti-tumor therapy. Immunotherapy in the tumor microenvironment stimulates immune function, enhances anti-tumor immunity, and then directly recognizes and kills tumor cells. At present, multiple immunotherapies have been utilized to treat tumors, such as immune checkpoint therapy, cytokines, tumor vaccines, adoptive cellular immunotherapy （ACI）, etc. ACI can kill tumor cells without compromising the immune system and function, and avoid tumor immune escape, which has become a research hot spot at home and abroad. The genetically-modified T cell is the deepest field in the clinical application of ACI. The genetically-modified T cells can be divided into chimeric antigen receptor T cells （CAR-T） and T-cell receptor-modified T cells （TCR-T）. In this article, the research progress on CAR-T and TCR-T therapies was reviewed.